Cargando…
Safety and Efficacy of Caproamin Fides and Tranexamic Acid Versus Placebo in Patients Undergoing Coronary Artery Revascularization
Introduction: Excessive fibrinolysis contributes to post-cardiopulmonary bypass bleeding. Tranexamic Acid (TXA) and Caproamin Fides are synthetic lysine analogues that inhibit plasminogen-fibrin binding. The present study aimed to compare TXA and Caproamin Fides versus placebo in patients undergoing...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tabriz University of Medical Sciences
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195972/ https://www.ncbi.nlm.nih.gov/pubmed/25320669 http://dx.doi.org/10.15171/jcvtr.2014.011 |
_version_ | 1782339396785143808 |
---|---|
author | Alizadeh Ghavidel, Alireza Totonchi, Ziae Chitsazan, Mitra Gholampour Dehaki, Maziar Jalili, Farshid Farsad, Fariborz Hejrati, Maral |
author_facet | Alizadeh Ghavidel, Alireza Totonchi, Ziae Chitsazan, Mitra Gholampour Dehaki, Maziar Jalili, Farshid Farsad, Fariborz Hejrati, Maral |
author_sort | Alizadeh Ghavidel, Alireza |
collection | PubMed |
description | Introduction: Excessive fibrinolysis contributes to post-cardiopulmonary bypass bleeding. Tranexamic Acid (TXA) and Caproamin Fides are synthetic lysine analogues that inhibit plasminogen-fibrin binding. The present study aimed to compare TXA and Caproamin Fides versus placebo in patients undergoing elective coronary artery revascularization. Methods: We analyzed perioperative data of 300 adult patients undergoing coronary artery revascularization. Patients were randomly allocated to receive TXA (n=100), Caproamin Fides (n=100) or placebo (n=100) during perioperative time. Mediastinal bleeding during the first 24 hours post-operation, transfusion requirement and post-surgical complications were assessed. Results: Most descriptive and intra-operative parameters were well comparable between the 3 study groups. Except for mean number of packed red blood cell (PRBC) units transfused during ICU stay (P=0.01), patients in the Caproamin Fides and TXA groups did not show any statistically significant differences regarding transfusion of blood products during peri-operative period. There was no evidence of a significant difference in mediastinal blood loss during the first 24 hours post-operation between the patients receiving TXA or placebo, while patients in the Caproamin Fides group had significantly lower mediastinal bleeding than the other 2 groups (Caproamin Fides vs. placebo, P=0.002, <0.001 and <0.001 at 6, 12 and 24 hours post-operation; Caproamin Fides vs. TXA, P=0.009, 0.003, <0.001 at 6, 12 and 24 hours post-operation). The incidence of postoperative complications were comparable between Caproamin Fides and TXA groups (P>0.05). Conclusion: In conclusion, Caproamin Fides seems to be superior to TXA regarding the blood saving effects in patients undergoing coronary artery revascularization. |
format | Online Article Text |
id | pubmed-4195972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Tabriz University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-41959722014-10-15 Safety and Efficacy of Caproamin Fides and Tranexamic Acid Versus Placebo in Patients Undergoing Coronary Artery Revascularization Alizadeh Ghavidel, Alireza Totonchi, Ziae Chitsazan, Mitra Gholampour Dehaki, Maziar Jalili, Farshid Farsad, Fariborz Hejrati, Maral J Cardiovasc Thorac Res Original Article Introduction: Excessive fibrinolysis contributes to post-cardiopulmonary bypass bleeding. Tranexamic Acid (TXA) and Caproamin Fides are synthetic lysine analogues that inhibit plasminogen-fibrin binding. The present study aimed to compare TXA and Caproamin Fides versus placebo in patients undergoing elective coronary artery revascularization. Methods: We analyzed perioperative data of 300 adult patients undergoing coronary artery revascularization. Patients were randomly allocated to receive TXA (n=100), Caproamin Fides (n=100) or placebo (n=100) during perioperative time. Mediastinal bleeding during the first 24 hours post-operation, transfusion requirement and post-surgical complications were assessed. Results: Most descriptive and intra-operative parameters were well comparable between the 3 study groups. Except for mean number of packed red blood cell (PRBC) units transfused during ICU stay (P=0.01), patients in the Caproamin Fides and TXA groups did not show any statistically significant differences regarding transfusion of blood products during peri-operative period. There was no evidence of a significant difference in mediastinal blood loss during the first 24 hours post-operation between the patients receiving TXA or placebo, while patients in the Caproamin Fides group had significantly lower mediastinal bleeding than the other 2 groups (Caproamin Fides vs. placebo, P=0.002, <0.001 and <0.001 at 6, 12 and 24 hours post-operation; Caproamin Fides vs. TXA, P=0.009, 0.003, <0.001 at 6, 12 and 24 hours post-operation). The incidence of postoperative complications were comparable between Caproamin Fides and TXA groups (P>0.05). Conclusion: In conclusion, Caproamin Fides seems to be superior to TXA regarding the blood saving effects in patients undergoing coronary artery revascularization. Tabriz University of Medical Sciences 2014 2014-09-30 /pmc/articles/PMC4195972/ /pubmed/25320669 http://dx.doi.org/10.15171/jcvtr.2014.011 Text en © 2014 The Author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Alizadeh Ghavidel, Alireza Totonchi, Ziae Chitsazan, Mitra Gholampour Dehaki, Maziar Jalili, Farshid Farsad, Fariborz Hejrati, Maral Safety and Efficacy of Caproamin Fides and Tranexamic Acid Versus Placebo in Patients Undergoing Coronary Artery Revascularization |
title | Safety and Efficacy of Caproamin Fides and Tranexamic Acid Versus Placebo in Patients Undergoing Coronary Artery Revascularization |
title_full | Safety and Efficacy of Caproamin Fides and Tranexamic Acid Versus Placebo in Patients Undergoing Coronary Artery Revascularization |
title_fullStr | Safety and Efficacy of Caproamin Fides and Tranexamic Acid Versus Placebo in Patients Undergoing Coronary Artery Revascularization |
title_full_unstemmed | Safety and Efficacy of Caproamin Fides and Tranexamic Acid Versus Placebo in Patients Undergoing Coronary Artery Revascularization |
title_short | Safety and Efficacy of Caproamin Fides and Tranexamic Acid Versus Placebo in Patients Undergoing Coronary Artery Revascularization |
title_sort | safety and efficacy of caproamin fides and tranexamic acid versus placebo in patients undergoing coronary artery revascularization |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195972/ https://www.ncbi.nlm.nih.gov/pubmed/25320669 http://dx.doi.org/10.15171/jcvtr.2014.011 |
work_keys_str_mv | AT alizadehghavidelalireza safetyandefficacyofcaproaminfidesandtranexamicacidversusplaceboinpatientsundergoingcoronaryarteryrevascularization AT totonchiziae safetyandefficacyofcaproaminfidesandtranexamicacidversusplaceboinpatientsundergoingcoronaryarteryrevascularization AT chitsazanmitra safetyandefficacyofcaproaminfidesandtranexamicacidversusplaceboinpatientsundergoingcoronaryarteryrevascularization AT gholampourdehakimaziar safetyandefficacyofcaproaminfidesandtranexamicacidversusplaceboinpatientsundergoingcoronaryarteryrevascularization AT jalilifarshid safetyandefficacyofcaproaminfidesandtranexamicacidversusplaceboinpatientsundergoingcoronaryarteryrevascularization AT farsadfariborz safetyandefficacyofcaproaminfidesandtranexamicacidversusplaceboinpatientsundergoingcoronaryarteryrevascularization AT hejratimaral safetyandefficacyofcaproaminfidesandtranexamicacidversusplaceboinpatientsundergoingcoronaryarteryrevascularization |